Navigation Links
NexGen Biofuels Ltd. (Nasdaq: NXGN) Announces Receipt of Nasdaq Delisting Determination

NEW YORK, February 27 /PRNewswire-FirstCall/ -- NexGen Biofuels Ltd. (f/k/a Healthcare Technologies Ltd.) (the "Company") announced today that on February 26, 2008, the Company received a letter from the Nasdaq Listing Qualification Panel, informing the Company that the Panel had determined to delist the Company's ordinary shares from The Nasdaq Stock Market following a determination by the Staff of the Nasdaq Listing Qualifications Department that the Company had failed to meet the Nasdaq listing standards for a reverse merger in connection with the Company's Plan of Arrangement with NexGen Biofuels Inc. Nasdaq will suspend trading of the Company's ordinary shares effective at the open of business on Thursday, February 28, 2008.

The Company believes that, following the recent filing of a Form 211 by a market maker, its ordinary shares will be eligible for trading on the OTC Bulletin Board.

For more information on NexGen Biofuels, Inc., visit

Safe harbor: This press release contains certain forward looking statements within the meaning of section 27a of the securities act of 1933 and section 21e of the securities exchange act of 1934. With the exception of historical information contained herein, the matters discussed in this press release involve risk and uncertainties. Actual results could differ materially from those expressed in any forward-looking statement made by or on behalf of healthcare technologies ltd. Readers are referred to the documents filed by the company with the securities and exchange commission, specifically the form 8-k/a filed on February 12, 2008 that identifies important risks which could cause actual results to differ from those contained in the forward looking statements.

Contact: Eran Rotem CFO, +972-3-9277232

SOURCE NexGen Biofuels Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Healthcare Technologies Ltd. Announces the Change of its Name to "NexGen Biofuels Ltd"
2. Healthcare Announced That an Overwhelming Majority of its Shareholders Approved the NexGen Biofuels Transaction
3. NexGenix Pharmaceuticals Enters into Exclusive World-wide License to Develop Novel Hsp90 Inhibitors
4. Healthcare Technologies Calls for a Shareholders Meeting to Approve the Nexgen Biofuels Transaction
5. N.C. Takes Biofuels Leadership, Establishes New Endeavor With $5 Million State Appropriation
6. Graceway Pharmaceuticals, LLC(TM) Announces Completed Acquisition of All Assets Related to Estrasorb(R) Product Line in North America From Allergan, Inc. (NYSE: AGN) and Novavax, Inc. (Nasdaq: NVAX)
7. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q2/08 Review Issued By Scimitar Equity Research, Inc.
8. Sigma-Aldrich (Nasdaq: SIAL) Annual Sales Surpass $2 Billion Mark.
9. QIAGEN N.V. (Nasdaq: QGEN) Invites You to Join Its Fourth Quarter and Year End 2007 Earnings and 2008 Guidance Conference Call on the Web
10. Healthcare Technologies Ltd. (NASDAQ: HCTL) Announces Extension of Letters of Intent to Acquire Majority Interest in Two Ethanol Plants
11. HealthCare Technologies Ltd. (NASDAQ: HCTL) Announces Receipt of NASDAQ Delisting Notice
Post Your Comments:
(Date:11/30/2015)... ... November 30, 2015 , ... Global Stem Cells Group announced the opening of a ... of Arica and Iquique in northern Chile. The facilities are part of GSCG’s expansion efforts ... protocols and techniques in stem cell medicine to patients from around the world. , The ...
(Date:11/30/2015)... , Nov. 30, 2015 Harvard ... ), a biotechnology company developing bioengineered organ implants ... written notification from The NASDAQ Stock Market that ... price requirements. The letter noted that as a ... common stock having exceeded $1.00 per share for ...
(Date:11/30/2015)... , Nov. 30, 2015 Human Longevity, Inc. ... company has acquired Cypher Genomics, Inc., a leading genome ... genomic interpretation software solutions. The San Diego ... HLI including Cypher CEO and Co-founder, Ashley Van Zeeland ... Pediatric Business.  Financial details of the deal were not ...
(Date:11/30/2015)... Germany , November 30, 2015 ... Vienna, Austria to be held December 1-4, 2015. ... in Vienna, Austria to be held ... subsidiary of Vycor Medical, Inc. ("Vycor") (OTCQB: VYCO), announced that ... Suite at the 3rd European Congress of NeuroRehabilitation (ECNR) ...
Breaking Biology Technology:
(Date:11/16/2015)... JOSE, Calif. , Nov 16, 2015 /PRNewswire/ ... developer of human interface solutions, today announced expansion ... Synaptics TouchView ™ touch controller and display ... architectural revolution of smartphones. These new TDDI products ... include TD4100 (HD resolution), TD4302 (WQHD resolution), and ...
(Date:11/10/2015)...  In this report, the biomarkers market ... type, application, disease indication, and geography. The ... consumables, services, software. The type segments included ... biomarkers, and validation biomarkers. The applications segments ... drug discovery and development, personalized medicine, disease ...
(Date:11/2/2015)... 2, 2015  SRI International has been awarded a ... development services to the National Cancer Institute (NCI) PREVENT ... scientific expertise, modern testing and support facilities, and analytical ... and toxicology studies to evaluate potential cancer prevention drugs. ... PREVENT Cancer Drug Development Program is an NCI-supported pipeline ...
Breaking Biology News(10 mins):